Deep Industry Knowledge and Technical Expertise.
With attorneys that include former scientists, professional chemists, patent examiners and chemical engineers with extensive practical experience in genetic engineering, Milbank’s Biotechnology Team has a thorough comprehension of all aspects of the biotechnology industry. Our attorneys routinely apply their technical expertise to a variety of technologies in the context of client counseling, litigation, licensing and prosecution.
Broad Spectrum of Experience
Our attorneys handle all types of biotechnology matters with representative technical experience including genetically-engineered enzymes, biosynthetic methods, recombinant proteins, immunology, nucleic acid synthesis and amplification, diagnostic methods, bioremediation and therapeutics. We are at the forefront in counseling and developing litigation strategies for the new biosimilars legislation and regulations. In addition to litigation, we have extensive expertise in complex licensing of patented technology and know how, counseling, patent prosecution, interferences and reexaminations, pre-litigation and M&A IP due diligence for the chemistry, pharmaceutical and biotechnology industries.
Our attorneys have been acknowledged by The National Law Journal as among the nation’s top trial lawyers and recognized in Chambers USA for Intellectual Property. Our publications have been cited by courts, recognized nationwide, and bestowed the "Burton Award for Best Law Firm Publication".
A Team Approach
We strive to serve as an extension of inside counsel by dedicating a lean group of attorneys, who make a genuine effort to know the client and the client’s business in depth. Our team’s approach is to make the client feel comfortable asking any member of our team any question at any time without watching the clock. We consider it our shared responsibility to diligently and efficiently prepare in advance for challenges, whether they be patent enforcement or defense, licensing in or out, or day to day strategy and counseling so that together we can navigate the minefield of the competitive, ever-evolving biotechnology industry.